Sacubitril-valsartan not tied to lower death risk versus ramipril in acute myocardial infarction: Study

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-12-04T09:00:14+05:30 | Updated On 13 Oct 2023 3:31 PM IST

USA: A recent study suggests that in patients with acute myocardial infarction, sacubitril-valsartan did not significantly lower death risk from cardiovascular causes or incident heart failure versus ramipril. The study appears in the New England Journal of Medicine.

Previous trials have shown sacubitril–valsartan to reduce the risk of hospitalization and death from cardiovascular causes in patients with symptomatic heart failure more effectively than an angiotensin-converting–enzyme inhibitor. However, trials comparing the effects of these drugs in patients with acute myocardial infarction are lacking. To fill this knowledge gap Marc A. Pfeffer and the team aimed to compare the effects of these drugs in patients with acute myocardial infarction.

The study included patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both. 5661 patients were randomly assigned to receive either sacubitril–valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily; n=2830) or ramipril (5 mg twice daily; n=2831) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first.

The study revealed the following findings:

Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril–valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90).
Death from cardiovascular causes or hospitalization for heart failure occurred in 10.9% of patients in the sacubitril–valsartan group and in 11.8% of patients in the ramipril group (hazard ratio, 0.91); death from cardiovascular causes in 5.9% and 6.7%, respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 7.5% and 8.5%, respectively (hazard ratio, 0.88).
Treatment was discontinued because of an adverse event in 12.6% of patients in the sacubitril–valsartan group and 13.4% of patients in the ramipril group.

"Our study found that sacubitril–valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction," concluded the authors.

Reference:

The study titled, "Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction," is published in the New England Journal of Medicine.

DOI: https://www.nejm.org/doi/full/10.1056/NEJMoa2104508

sacubitrilvalsartanacute myocardial infarctionNEJM

Source : New England Journal of Medicine

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751